Screener
Royalty Pharma RPRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Accounts payable and accrued liabilities | 35,566 | 19,404 |
| Interest payable | 107,766 | 110,818 |
| Current portion of long-term debt | 380,000 | 380,000 |
| Other current liabilities | 16,316 | 53,164 |
| Total current liabilities | 630,928 | 636,211 |
| Long-term debt | 8,581,892 | 8,570,917 |
| Accrued compensation liabilities | 713,219 | 577,870 |
| Other liabilities | 108,018 | 120,843 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's accrued expenses?
- Royalty Pharma (RPRX) reported accrued expenses of $16.32M in Q2 2026.
- How has Royalty Pharma's accrued expenses changed year-over-year?
- Royalty Pharma's accrued expenses increased by 430.6% year-over-year, from $3.08M to $16.32M.
- What is the long-term trend for Royalty Pharma's accrued expenses?
- Over 3 years (2022 to 2025), Royalty Pharma's accrued expenses has grown at a 62.5% compound annual growth rate (CAGR), from $12.4M to $53.16M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Royalty Pharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude